LXRX (Lexicon Pharmaceuticals, Inc. )

[felixbocharov]

On August 3, the company reported positive results from its TELESTAR Phase 3 clinical trials. Results showed that the oral version of one of its main drugs candidate’s telotristat etiprate or LX1032 delivers a clinical benefit beyond what is possible with the current standard of care in the treatment of carcinoid syndrome patients. This is an addressable market that could see peak sales of $400 million to $550 million. The company also has other “shots on goal” and a market capitalization of just $1.3 billion.

Does somebody follow this stock?

 

[Michael J. Fletcher]

The company plans for the drug's regulatory approval with the U.S.Food and Drug Administration soon. Could be on the market sometime next year. I'm bullish here.

 

[Zestilio]

$LXRX took 1st slice +.11, room to manage risk, rode 9ema all day, offrd 1/2 + .21, remain 1/2 +.35

 

[felixbocharov]

Yeah, baby, we're on a new 52-week high! Making some $$$ here